Picture BIO Deutschland German Corona Special 2021 Digital 650x80px
Organisation › Details

Proteomedix AG

Proteomedix is a healthcare company whose mission is to transform prostate cancer diagnostics. The company has identified novel biomarker signatures with utility in prostate cancer diagnostics, prognostics and therapy management. Their lead product Proclarix® is a blood based prostate cancer test panel and risk score and will be introduced to the market early 2020. Proteomedix is located in the Biotechnopark of Schlieren, Switzerland. *


Period Start 2010-01-01 established (s-off
  Predecessor ETH Zürich (ETHZ)
Products Industry Proclarix® blood-based prostate cancer test panel and risk score
  Industry 2 personalised medicine / precision medicine
Persons Person Lubenow, Helge (Proteomedix 202001– CEO before Consultant before 1997–2015 at Qiagen)
  Person 2 Brühlmann, Christian (Proteomedix 202001 COO/CFO)
Region Region Schlieren ZH
  Country Switzerland
  Street 21 Wagistr.
  City 8952 Schlieren ZH
  Tel +41-44-733-4090
    Address record changed: 2020-12-02
Basic data Employees n. a.
    * Document for �About Section�: Proteomedix AG. (1/10/20). "Press Release: Proteomedix Appoints Helge Lubenow as New CEO". Zürich-Schlieren.
Record changed: 2020-05-26


Picture EBD Group Global Partnering Four Events One Price 650x80

More documents for Proteomedix AG

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [iito] Back into Ad 650x80px

» top